Accelerating Low-Cost Production of Consistent, Safe & Scalable Vectors for Cell & Gene Therapy to Ensure Regulatory Compliance
As more viral vector therapies advance towards commercialization, the industry's focus is shifting from novel vector discovery to optimizing manufacturing processes that reliably deliver scalable, cost-effective, and high-quality products. With growing pressure to increase productivity, reduce costs, and strengthen regulatory confidence, robust and reproducible manufacturing platforms are becoming critical to clinical and commercial success.
The 5th Viral Vector Process Development & Manufacturing Summit is the only conference dedicated to viral vector process development across AAV and LVV applications in cell and gene therapy to improve manufacturing productivity and process robustness.
Leaders from Alexion Pharma, Ultragenyx, Regeneron, Legend Biotech, Modalis Therapeutics are attending to benchmark your approaches with proven strategies, learn from real-world manufacturing experiences, and build more robust, reliable, and reproducible viral vector processes.
Join your peers to discover how to increase yields, optimize transfection and purification processes, leverage platform manufacturing strategies, improve analytical decision-making, and reduce manufacturing costs. Learn how to achieve this while maintaining the speed, quality, and consistency needed to advance programmes into the clinic and through to commercialization.
Improving manufacturability isn't just about operational excellence, it's about making life-changing therapies more accessible and affordable to the patients who need them most.
This conference provides an excellent opportunity to discuss the challenges and development of AAV with leading experts.
2027 Speaker, Associate Director, Cell Culture and Process Development, Genomic Medicine Unit, Sanofi
One of the biggest benefits of attending was the opportunity to learn from industry peers and hear real-world experiences firsthand. The meeting provided excellent insight into emerging technologies, evolving regulatory expectations, and the key challenges shaping gene and cell therapy development today.
2027 Speaker, Senior Director, Global CMC Development, Ultragenyx
The event harbored an intimate space where experts were able to let down their guard and discuss latest technology, data, & ideas. It seemed well thought out through the day with very attentive staff.
Director, CGT Unit, OcyonBio
Explore The Full Event Guide
- Explore proven strategies to increase yields and reduce manufacturing costs
- Benchmark platform manufacturing approaches accelerating clinical and commercial success
- Discover practical solutions for transfection, purification, and process scalability
- Learn how leading developers are improving robustness, reproducibility, and regulatory readiness
- Preview insights from experts at Ultragenyx, Regeneron, Legend Biotech, Alexion, Sanofi, and more
Official Partners
Attending Companies Include
Explore Related Events
Explore the Agenda
Discover proven strategies for increasing yields, reducing manufacturing costs, and building scalable viral vector platforms.
Partner With Us
Connect directly with the viral vector leaders seeking technologies, services, and partners to accelerate manufacturing success.
Join Viral Vector Leaders
Benchmark approaches with senior CMC, process development, manufacturing, MSAT, and regulatory experts advancing viral vector-based therapies.